Hazeldine Stuart T, Polin Lisa, Kushner Juiwanna, White Kathryn, Bouregeois Nicole M, Crantz Brianna, Palomino Eduardo, Corbett Thomas H, Horwitz Jerome P
Department of Internal Medicine, Division of Hematology and Oncology, Wayne State University School of Medicine, Detroit, MI, USA.
J Med Chem. 2002 Jul 4;45(14):3130-7. doi: 10.1021/jm0200097.
XK469 (1) is among the most highly and broadly active antitumor agents to have been evaluated in our laboratories. Subsequent developmental studies led to the entry of (R)-(+) 1 (NSC 698215) into phase 1 clinical trials (NIH UO1-CA62487). The antitumor mechanism of action of 1 remains to be elucidated, which has prompted a sustained effort to elaborate a pharmacophoric pattern of 1. The present study focused on a strategy of synthesis and biological evaluation of topologically based, bioisosteric replacements of the quinoxaline moiety in the lead compound (1) by quinazoline (4a-d), 1,2,4-benzotriazine (12a-18b), and quinoline (21a-g) ring systems. The synthetic approach to each of the bioisosteres of 1 utilized the methodology developed in previous work (see Hazeldine, S. T.; Polin, L.; Kushner, J.; Paluch, J.; White, K.; Edelstein, M.; Palomino, E.; Corbett, T. H.; Horwitz, J. P. Design, Synthesis, and Biological Evaluation of Analogues of the Antitumor Agent 2-(4-[(7-Chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469). J. Med. Chem. 2001, 44, 1758-1776.), which is extended to the procurement of the benzoxazole (23a,b), benzthiazole (23c,d), pyridine (25a,b), and pyrazine (27) congeners of 1. Only quinoline analogues, bearing a 7-halo (21a,b,d,e) or a 7-methoxy substituent (21g), showed antitumor activities (Br > Cl > CH(3)O > F approximately I), at levels comparable to or greater than the range of activities manifested by 1 and corresponding analogues. At high individual dosages, the (S)-(-) enantiomers of 1 and 21b,d all produce a reversible slowing of nerve-conduction velocity in the mice, the onset of which is characterized by a distinctive dysfunction of the hind legs, causing uncoordinated movements. The condition resolves within 5-10 min. However, at higher dosages, which approach a lethal level, the behavior extended to the front legs, lasting from 20 min to 1 h. By contrast, the (R)-(+) forms of these same agents did not induce the phenomenon of slowing of nerve-conduction velocity.
XK469 (1)是我们实验室评估过的活性最高且活性范围最广的抗肿瘤药物之一。后续的研发研究使得(R)-(+) 1 (NSC 698215)进入了1期临床试验(美国国立卫生研究院UO1-CA62487)。1的抗肿瘤作用机制仍有待阐明,这促使人们持续努力去阐述1的药效团模式。本研究聚焦于一种合成及生物学评估策略,即通过喹唑啉(4a - d)、1,2,4 -苯并三嗪(12a - 18b)和喹啉(21a - g)环系对先导化合物(1)中的喹喔啉部分进行基于拓扑学的生物电子等排体置换。合成1的每种生物电子等排体所采用的方法利用了先前工作中开发的方法(见Hazeldine, S. T.; Polin, L.; Kushner, J.; Paluch, J.; White, K.; Edelstein, M.; Palomino, E.; Corbett, T. H.; Horwitz, J. P. 抗肿瘤药物2-(4-[(7-氯-2-喹喔啉基)氧基]苯氧基)丙酸(XK469)类似物的设计、合成及生物学评估。《药物化学杂志》2001年,44卷,1758 - 1776页),该方法已扩展用于制备1的苯并恶唑(23a,b)、苯并噻唑(23c,d)、吡啶(25a,b)和吡嗪(27)类似物。只有带有7-卤代(21a,b,d,e)或7-甲氧基取代基(21g)的喹啉类似物显示出抗肿瘤活性(溴>氯>甲氧基>氟≈碘),其活性水平与1及相应类似物所表现出的活性范围相当或更高。在高个体剂量下,1和21b,d的(S)-(-)对映体均会使小鼠神经传导速度出现可逆性减慢,其发作特征为后腿明显功能障碍,导致运动不协调。这种情况在5 - 10分钟内会缓解。然而,在接近致死水平的更高剂量下,这种行为会扩展到前腿,持续20分钟至1小时。相比之下,这些相同药物的(R)-(+)形式不会诱发神经传导速度减慢的现象。